Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia

Next Previous
Trial Profile

A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atropine (Primary)
  • Indications Myopia
  • Focus Registrational; Therapeutic Use
  • Acronyms CHAMP
  • Sponsors Nevakar; Vyluma

Most Recent Events

  • 18 Jun 2024 According to a Vyluma media release, the Company had a Type A meeting with representatives of the U.S. Food and Drug Administration's (FDA's) Division of Ophthalmology to discuss the response to FDA's questions. The company will move forward with a submission to address FDA's questions in the third quarter of 2024.
  • 29 May 2024 According to a Vyluma media release, based on data from this trial the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for its lead compound, NVK002. The application is confirmed to be eligible for a Paediatric Use Marketing Authorisation (PUMA), providing 10 years of data exclusivity and marketing protection upon product approval.
  • 11 Oct 2023 Status changed from active, no longer recruiting to completed, according to a Vyluma media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top